Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS)
| Autor: | Marc Da Costa, Paul R. Heath, Janine Kirby, Esther Hobson, Rachel Waller, Jonathan Cooper-Knock, Pamela J. Shaw, Emily F. Goodall, Helen Wollff, Marta Milo, Mbombe Kazoka |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Serum 0301 basic medicine Aging Disease Biology Bioinformatics Polymerase Chain Reaction Cohort Studies 03 medical and health sciences 0302 clinical medicine microRNA Gene expression medicine Humans Longitudinal Studies Amyotrophic lateral sclerosis Wasting Aged Muscles General Neuroscience Amyotrophic Lateral Sclerosis Disease progression Regular Article MicroRNA Biomarker Middle Aged medicine.disease MicroRNAs 030104 developmental biology Potential biomarkers Cohort Immunology Disease Progression Female Neurology (clinical) Geriatrics and Gerontology medicine.symptom Biomarkers 030217 neurology & neurosurgery Developmental Biology |
| Zdroj: | Neurobiology of Aging |
| ISSN: | 0197-4580 |
| Popis: | Amyotrophic lateral sclerosis (ALS) is a fatal, neurodegenerative condition characterized by loss of motor neurones and progressive muscle wasting. There is no diagnostic test for ALS therefore robust biomarkers would not only be valuable for diagnosis, but also for the classification of disease subtypes, monitoring responses to drugs and tracking disease progression. As regulators of gene expression, microRNAs (miRNAs) are increasingly used for diagnostic and prognostic purposes in various disease states with increasing exploration in neurodegenerative disorders. We hypothesize that circulating blood-based miRNAs will serve as biomarkers and use miRNA profiling to determine miRNA signatures from the serum of sporadic ALS patients compared to healthy controls and patients with diseases that mimic ALS. A number of differentially expressed miRNAs were identified in each set of patient comparisons. Validation in an additional patient cohort showed that miR-206 and miR-143-3p were increased and miR-374b-5p was decreased compared to controls. A continued change in miRNA expression persisted during disease progression indicating the potential use of these particular miRNAs as longitudinal biomarkers in ALS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect